| ESBL (n = 122) | CPE (n = 119) | MDR-Acinetobacter (n = 62)a | MDR-Pseudomonas (n = 63)a | VRE (n = 72) | MRSA (n = 148) |
---|---|---|---|---|---|---|
(n = number of centers performing a targeted screening for each pathogen) | ||||||
Risk factors used for targeted admission screening (%) | ||||||
 Known MDRO patient: | 111 (91%) | 111 (93%) | 59 (95%) | 60 (95%) | 67 (93%) | 143 (97%) |
 Direct transfer from abroad: | 114 (93%) | 107 (90%) | 41 (66%) | 37 (59%) | 54 (75%) | 144 (97%) |
 Direct transfer from Switzerlandb: | 33 (27%) | 29 (24%) | 13 (21%) | 14 (22%) | 14 (19%) | 71 (48%) |
 Transfer from a long term care facility: | 11 (9%) | 7 (6%) | 3 (5%) | 4 (6%) | 5 (7%) | 32 (22%) |
 Hospitalization abroad in the recent pastc: | 103 (84%) | 98 (82%) | 37 (59%) | 32 (51%) | 47 (65%) | 109 (74%) |
 Travel in a country with endemic MDRO: | 28 (23%) | 34 (29%) | 16 (25%) | 18 (29%) | 19 (26%) | 35 (24%) |
 Other: | 38 (31%) | 41 (34%) | 23 (37%) | 21 (33%) | 21 (29%) | 84 (57%) |